Primary and secondary osteoarthritis; osteochondrosis; humerus periarthritis; fractures (to accelerate the formation of callus). Means used in the pathology of the musculoskeletal system.
Composition and form of release
Teraflex is manufactured in capsules. The drug contains – glucosamine hydrochloride and sodium chondroitin sulfate.
Teraflex is used in the complex therapy of diseases of the musculoskeletal system, characterized by degenerative-dystrophic changes in the articular tissue, which allows it to be used to treat:
- primary and secondary osteoarthritis;
- osteochondrosis of the spine;
- degenerative-dystrophic changes in the joints and spine;
- traumatic damage to bones (the drug stimulates regenerative processes and accelerates the formation of callus).
Teraflex is not prescribed if the patient has:
- severe renal failure;
- hypersensitivity to glucosamine hydrochloride or sodium chondroitin sulfate;
- pregnancy or lactation;
- age under 15.
Special care should be taken when prescribing Teraflex if the patient has a tendency to bleeding, diabetes mellitus or bronchial asthma.
Application during pregnancy and lactation
Due to the fact that clinical studies of the effect of Teraflex on the development of the fetus and newborn are absent, it is not used to treat this category of patients. If it is necessary to prescribe a remedy at the lactation stage, it is recommended to consider the question of stopping feeding.
Method of administration and dosage
Teraflex capsules are intended for oral administration. The drug is consumed regardless of food intake. Adults and children who have turned 15 years old for the first 3 weeks of treatment should take 1 capsule 3 times a day. In the future, the drug is recommended to take 1 capsule 2 times a day.
If there are no other recommendations, then the course of drug treatment can be from 3 to 6 months. If necessary, the duration of treatment can be changed taking into account the severity of the disease.
At the moment, there have been no officially registered cases of overdose during treatment with Teraflex. However, it is reliably known that when taking chondroitin sulfate in high doses, the patient may develop nausea, vomiting and hemorrhagic rashes.
If a patient develops symptoms of drug intoxication, he is prescribed gastric lavage and symptomatic treatment.
As a rule, patients tolerate Teraflex well. However, in some patients, its use may be accompanied by the development of abdominal pain, flatulence, stool disorders, constipation, headaches, peripheral edema, sleep disturbances, dizziness and various allergic reactions.
Storage conditions and periods
Teraflex must be stored in a dark, dry place out of the reach of children.
The shelf life of the medicinal product is 3 years.